Takeda and hutchmed announce new drug application (nda) for fruquintinib for treatment of previously treated metastatic colorectal cancer granted priority review

Osaka, japan & cambridge, mass. & hong kong & shanghai & florham park, n.j.--(business wire)--takeda (tse:4502/nyse:tak) and hutchmed (china) limited (nasdaq/aim:hcm, hkex:13) (hutchmed) today announced that the u.s. food and drug administration (fda) has granted priority review of the new drug application (nda) for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors (vegfr) -1, -2 and -3 for the treatment of adult patients with previously treat.
TAK Ratings Summary
TAK Quant Ranking